Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.
What happened
FDA inspected Synergy Animal Products’ Bethel, PA facility from September 5 through September 10, 2024, and then reviewed the company’s website. FDA found the company marketed products with claims to treat or prevent disease in dairy cows, making them unapproved new animal drugs, and that labeling lacked adequate directions for use. FDA also found no drug registration or listing and major current good manufacturing practice (CGMP) failures, including no quality unit, no testing, no written production records, and visibly dirty equipment.
What FDA found
The company marketed Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint with claims that they treat or prevent disease in animals, so they are unapproved new animal drugs—drugs not FDA-approved for those uses.
FD&C Act §§ 201(g)(1), 201(v), 512(a) [21 U.S.C. §§ 321(g)(1), 321(v), 360b(a)]The product labeling lacks adequate directions for use, including clear indications, routes, and frequency, in language laypersons can understand.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The company did not register its drug manufacturing establishment with FDA or list the animal drugs it makes.
FD&C Act §§ 510(b), (j), 502(o) [21 U.S.C. §§ 360(b), (j), 352(o)]The company had no quality unit to approve or reject procedures, components, labeling, and drug products.
21 CFR 211.22The company did not test incoming components for identity and did not test finished drug products for identity, strength, quality, and purity.
21 CFR 211.84(d); 21 CFR 211.165(a)The company had no master production and control records or batch records and no written cleaning and maintenance procedures, and FDA observed visibly dirty equipment.
21 CFR 211.186(a), 211.188, 211.67
What FDA wants
Within 15 working days of receipt, FDA tells the company to notify the agency in writing of specific corrective steps, how it will prevent recurrence, and supporting documents; if corrections are not complete, explain the delay and completion date. FDA also recommends engaging a qualified CGMP consultant to audit operations and help meet CGMP.
Who should pay attention
- dairy farmers who buy udder-health products
- veterinarians advising dairy producers
- companies making or selling animal drugs for food-producing animals
This is a summary. Read the original letter on fda.gov.